Evidence map›Paper›PMID 38750435›Full record

ArticleBiological procedures online2024

Breaking the Mucin Barrier: A New Affinity Chromatography-Mass Spectrometry Approach to Unveil Potential Cell Markers and Pathways Altered in Pseudomyxoma Peritonei.

Antonio Romero-Ruiz, Melissa Granados-Rodríguez, Florina I Bura, Francisca Valenzuela-Molina, Blanca Rufián-Andújar, Ana Martínez-López, Lidia Rodríguez-Ortiz, Rosa Ortega-Salas, María Torres-Martínez, Ana Moreno-Serrano and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological procedures online, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Antonio Romero-Ruiz *Department of Biochemistry and Molecular Biology, University of Córdoba, Córdoba, Spain. b72rorua@uco.es.
Melissa Granados-Rodríguez *Department of Biochemistry and Molecular Biology, University of Córdoba, Córdoba, Spain.
Florina I BuraDepartment of Biochemistry and Molecular Biology, University of Córdoba, Córdoba, Spain.
Francisca Valenzuela-MolinaMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.
Blanca Rufián-AndújarMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.
Ana Martínez-LópezMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.
Lidia Rodríguez-OrtizMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.
Rosa Ortega-SalasMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.
María Torres-MartínezDepartment of Biochemistry and Molecular Biology, University of Córdoba, Córdoba, Spain.
Ana Moreno-SerranoMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.
Justo CastañoDepartment of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Carmen MichánDepartment of Biochemistry and Molecular Biology, University of Córdoba, Córdoba, Spain.
José AlhamaDepartment of Biochemistry and Molecular Biology, University of Córdoba, Córdoba, Spain.
Mari C Vázquez-BorregoMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain. carmen.vazquez@imibic.org.
Álvaro Arjona-SánchezMaimonides Biomedical Research Institute of Córdoba, IMIBIC and University of Córdoba, Av. Menéndez Pidal, s/n, Córdoba, 14004, Spain.

Funding

Fundación Científica Asociación Española Contra el Cáncer PRYES223170ARJOInstituto de Salud Carlos III PI22/01213
6 · The paper itself

Abstract

backgroundPseudomyxoma peritonei (PMP) is a rare peritoneal mucinous carcinomatosis with largely unknown underlying molecular mechanisms. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the only therapeutic option; however, despite its use, recurrence with a fatal outcome is common. The lack of molecular characterisation of PMP and other mucinous tumours is mainly due to the physicochemical properties of mucin.

resultsThis manuscript describes the first protocol capable of breaking the mucin barrier and isolating proteins from mucinous tumours. Briefly, mucinous tumour samples were homogenised and subjected to liquid chromatography using two specific columns to reduce mainly glycoproteins, albumins and immunoglobulin G. The protein fractions were then subjected to mass spectrometry analysis and the proteomic profile obtained was analysed using various bioinformatic tools. Thus, we present here the first proteome analysed in PMP and identified a distinct mucin isoform profile in soft compared to hard mucin tumour tissues as well as key biological processes/pathways altered in mucinous tumours. Importantly, this protocol also allowed us to identify MUC13 as a potential tumour cell marker in PMP.

conclusionsIn sum, our results demonstrate that this protein isolation protocol from mucin will have a high impact, allowing the oncology research community to more rapidly advance in the knowledge of PMP and other mucinous neoplasms, as well as develop new and effective therapeutic strategies.

Indexed as

CancerMUC13MucinProteinPseudomyxoma peritonei

Identifiers

PMID38750435
PMCPMC11094946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.